Preliminary in vivo evaluation of [131I]-2-I-D-Phe as a potential radionuclide therapeutic agent in R1M-fluc rhabdomyosarcoma tumour bearing NuNu mice using bioluminescent imaging

Matthias Bauwens, Lena Wimana, Marleen Keyaerts, Cindy Peleman, Tony Lahoutte, Ken Kersemans, Sarah Snykers, Mathieu Vinken, John Mertens, Axel Bossuyt

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND:

Carrier-added [(123)I]-2-iodo-D-phenylalanine (CA [(123)I]-2-I-D-Phe) was previously found to have a preferential retention in tumors with a high tumor background contrast in animal models. A previous human dosimetry study demonstrated a favorable biodistribution and radiation burden in human subjects.

AIM:

The aim of this study was to investigate the potential of CA [(131)I]-2-I-D-Phe as an agent for radionuclide therapy.

METHODS:

Sixty (60) nude athymic mice were inoculated subcutaneously with firefly luciferase-transduced R1M rhabdomyosarcoma cells. The mice in the therapy group were injected intravenously (i.v.) with 148 MBq [(131)I]-2-I-D-Phe (432 GBq/mmol) in kit solution. Controls were injected with kit solution without radioactivity, with physiological saline, or with 148 MBq [(131)I](-) in physiological saline. Tumor growth was quantified using bioluminescent imaging and caliper measurements.

RESULTS:

[(131)I]-2-I-D-Phe clearly reduced tumor growth in the treated mice compared with the control groups. A tumor growth-rate reduction of at least 33% was found for mice receiving a therapeutic dose. There were no serious adverse side-effects of the therapy.

CONCLUSIONS:

In conclusion, i.v. injection of CA 148 MBq [(131)I]-2-I-D-Phe specifically reduces tumor growth in athymic nude mice without relevant side-effects on the animals' health.
Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalCancer Biotherapy and Radiopharmaceuticals
Volume25
Publication statusPublished - 1 Apr 2010

Keywords

  • radionuclide

Fingerprint

Dive into the research topics of 'Preliminary in vivo evaluation of [131I]-2-I-D-Phe as a potential radionuclide therapeutic agent in R1M-fluc rhabdomyosarcoma tumour bearing NuNu mice using bioluminescent imaging'. Together they form a unique fingerprint.

Cite this